Sorry, I don't understand your search. ×
Back to Search Start Over

264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors :
Kelly, W.K.
Danila, D.C.
Lin, C-C.
Lee, J-L.
Matsubara, N.
Ward, P.J.
Armstrong, A.J.
Pook, D.W.
Kim, M.
Dorff, T.
Fischer, S.
Lin, Y-C.
Horvath, L.G.
Sumey, C.
Yang, Z.
Jurida, G.
Connarn, J.
Penny, H.
Stieglmaier, J.
Appleman, L.J.
Source :
Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1576-S1576. 1p.
Publication Year :
2023

Subjects

Subjects :
*CASTRATION-resistant prostate cancer
*CD3 antigen

Details

Language :
English
ISSN :
09237534
Volume :
34
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
173758273
Full Text :
https://doi.org/10.1016/j.annonc.2023.10.390
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details